Johnson & Johnson (NYSE:JNJ) Shares Bought by Donaldson Capital Management LLC

Donaldson Capital Management LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 343,944 shares of the company’s stock after purchasing an additional 7,092 shares during the quarter. Johnson & Johnson comprises 2.1% of Donaldson Capital Management LLC’s investment portfolio, making the stock its 19th biggest position. Donaldson Capital Management LLC’s holdings in Johnson & Johnson were worth $55,740,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. raised its stake in Johnson & Johnson by 2.6% during the third quarter. Robeco Institutional Asset Management B.V. now owns 1,390,984 shares of the company’s stock worth $225,423,000 after purchasing an additional 35,717 shares during the period. Lansing Street Advisors raised its position in shares of Johnson & Johnson by 1.8% during the 3rd quarter. Lansing Street Advisors now owns 5,607 shares of the company’s stock valued at $909,000 after buying an additional 101 shares during the period. BSW Wealth Partners lifted its holdings in Johnson & Johnson by 2.2% in the third quarter. BSW Wealth Partners now owns 6,738 shares of the company’s stock valued at $1,092,000 after acquiring an additional 143 shares during the last quarter. Angeles Wealth Management LLC grew its position in Johnson & Johnson by 22.2% in the third quarter. Angeles Wealth Management LLC now owns 15,837 shares of the company’s stock worth $2,567,000 after acquiring an additional 2,877 shares during the period. Finally, Van ECK Associates Corp raised its position in Johnson & Johnson by 12.7% in the third quarter. Van ECK Associates Corp now owns 780,186 shares of the company’s stock valued at $129,401,000 after purchasing an additional 88,107 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Citigroup raised their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. TD Securities decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Wells Fargo & Company increased their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $158.24 on Tuesday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $380.98 billion, a PE ratio of 22.90, a price-to-earnings-growth ratio of 2.84 and a beta of 0.52. The business’s fifty day moving average price is $163.18 and its 200 day moving average price is $155.68.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.13%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.